Skip to main content

Health condition · Clinically reviewed

Malignant peripheral nerve sheath tumours, a rare sarcoma that demands rapid specialist care.

Strongly linked to neurofibromatosis type 1 - new or changing pain in a known neurofibroma is the warning sign that should never be ignored.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, ESMO sarcoma guidelines and NF1 surveillance standards you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance including specialist commissioned MRI, biopsy pathways and selumetinib for NF1-associated plexiform neurofibroma.

Key facts

MPNST at a glance.

The essentials, in plain English - what it is, why NF1 matters, and how it's investigated and treated in the UK today.

  • What it is

    A rare, aggressive sarcoma arising from Schwann cells or other peripheral nerve sheath cells, capable of rapid local growth and distant spread.

  • NF1 link

    Up to half of all MPNSTs arise in people with neurofibromatosis type 1, usually from malignant change in an existing plexiform neurofibroma.

  • Lifetime risk

    Around 10% of people with NF1 will develop an MPNST at some point in their lives - far above the risk in the general population.

  • Key warning sign

    New or changing pain in a known neurofibroma is the classic red flag for malignant transformation and needs urgent assessment.

  • Diagnosis

    MRI first, often followed by PET-CT and a mandatory core needle biopsy before any treatment decision is made.

  • Main treatment

    Wide surgical resection is the mainstay, often combined with radiotherapy - chemotherapy is reserved for metastatic or unresectable disease.

Why this guide matters

Rare, aggressive, and time-sensitive.

MPNST is uncommon but unforgiving if missed. The three points below shape everything else on this page.

  • NF1 changes the whole picture

    If you have neurofibromatosis type 1, any new or changing lesion is assessed with a much higher index of suspicion than in the general population.

  • Pain is the earliest signal

    New or worsening pain in a known neurofibroma often precedes visible growth - it should never be put down to "just a lump".

  • Biopsy always comes before treatment

    However convincing the imaging looks, a core needle biopsy confirms the diagnosis before surgery, radiotherapy or chemotherapy is planned.

How the diagnosis is made

From suspicion to a confirmed plan.

The steps a UK sarcoma or NF1 specialist team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    High index of suspicion

    In anyone with NF1, a lesion that is enlarging, newly painful or growing quickly is treated as malignant until proven otherwise.

  2. 02

    Assessing

    Clinical and neurological exam

    Assessment of the mass itself alongside motor and sensory testing in the distribution of the affected nerve.

  3. 03

    Confirming

    MRI - the gold standard

    Specialist commissioned MRI (see our private MRI scan guide) maps the tumour, its relationship to the nerve and surrounding structures.

  4. 04

    Confirming

    PET-CT for malignant change

    Specialist commissioned PET-CT at NF1 centres helps distinguish a benign plexiform neurofibroma from one undergoing malignant transformation through increased uptake.

  5. 05

    Confirming

    Core needle biopsy

    A specialist commissioned sarcoma pathology biopsy is mandatory before any treatment begins - imaging alone is never enough to confirm MPNST.

  6. 06

    Planning

    Molecular and staging work-up

    Specialist commissioned tumour molecular profiling for NF1, CDKN2A and PRC2 loss, alongside CT of the chest, abdomen and pelvis to check for spread.

  7. 07

    Planning

    Specialist MDT discussion

    Every case is reviewed by a specialist commissioned sarcoma centre working alongside NF1 specialist services such as those in Manchester and at Guy’s.

Typical timeline: rapid escalation from first suspicion to MDT-agreed plan, usually within days to a few weeks.

Symptoms

What malignant transformation looks like.

The classic combination of an enlarging mass, new pain and nerve symptoms - and the feature that means it's time to seek urgent help.

  • Enlarging mass

    Often at the site of a pre-existing neurofibroma in someone with NF1 - the single most common presenting feature.

  • New or changed pain

    Pain that is new, worsening or different in character within a known neurofibroma is a red flag for malignant transformation.

  • Motor or sensory deficit

    Weakness, numbness or tingling in the distribution of the affected nerve as the tumour compresses or invades it.

  • Rapid growth

    A lesion that has clearly increased in size over weeks to months, rather than staying stable for years.

  • Firm, fixed texture

    A mass that feels harder or more fixed to surrounding tissue than the soft, mobile texture of a benign neurofibroma.

  • Systemic symptoms

    Unexplained weight loss, fatigue or night sweats can accompany more advanced or metastatic disease.

  • Prior radiotherapy site

    MPNST can arise sporadically or years after radiotherapy to a nearby area, even without NF1.

  • Red flag - pain in a known neurofibroma

    New or changing pain in an established neurofibroma should always trigger urgent specialist assessment.

Treatment

How MPNST is treated in the UK.

Wide surgical resection first, with radiotherapy, chemotherapy and emerging targeted options for higher-risk or metastatic disease.

  • Wide surgical resection

    Specialist commissioned sarcoma surgery aiming for clear margins - the mainstay of curative treatment, often requiring nerve sacrifice.

  • Adjuvant radiotherapy

    Specialist commissioned radiotherapy for high-grade tumours or close surgical margins, to reduce the risk of local recurrence.

  • Chemotherapy

    Doxorubicin and ifosfamide-based regimens for metastatic or unresectable disease - MPNST is relatively chemo-resistant, so response can be limited.

  • MEK inhibitors

    Selumetinib (see our NF1 clinic guide) is approved for NF1-associated plexiform neurofibroma and has an emerging role in the wider management pathway.

  • NF1 whole-body MRI surveillance

    Specialist commissioned surveillance imaging in people with NF1 aims to catch malignant transformation as early as possible.

  • Metastatic disease management

    Palliative chemotherapy and specialist commissioned best supportive care focused on symptom control and quality of life.

  • Molecular profiling

    Specialist commissioned tumour molecular profiling to inform prognosis, trial eligibility and, where relevant, targeted approaches.

  • MDT and support services

    Ongoing input from specialist commissioned sarcoma and NF1 services, alongside charities such as Sarcoma UK and Nerve Tumours UK.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist sarcoma society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP, NF1 specialist or sarcoma team knows your history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Suspected cancer: recognition and referral, and sarcoma-specific guidance.

  • ESMO. Soft tissue and visceral sarcomas: clinical practice guidelines.

  • European Reference Network on rare cancers - guidance on NF1-related tumours.

  • MHRA. Selumetinib for NF1-associated plexiform neurofibroma - prescribing information.

Red flags

When a neurofibroma needs urgent attention.

Most neurofibromas stay stable for years. These are the situations that suggest malignant transformation and need rapid specialist review.

  • New pain in a known neurofibroma

    The single most important warning sign of malignant transformation in someone with NF1 - never dismiss it as unrelated.

  • Rapidly enlarging mass

    A lesion that has clearly grown over weeks rather than years needs urgent imaging and biopsy.

  • New neurological deficit

    Sudden weakness, numbness or loss of function in a limb suggests nerve invasion and needs same-week specialist assessment.

  • Firm, fixed or tender lesion

    A change in texture from soft and mobile to hard and fixed is a signal that should not be watched and waited on.

  • Unexplained systemic symptoms

    Weight loss, fatigue or night sweats alongside a growing mass raise concern for more advanced disease.

  • Delay in specialist referral

    MPNST grows quickly - any suspicious change deserves rapid referral to a sarcoma or NF1 specialist centre, not routine follow-up.

  • Prior radiotherapy field changes

    A new mass in a previously irradiated area, even without NF1, should be investigated as a possible radiation-associated MPNST.

  • Skipping biopsy before treatment

    Imaging alone cannot confirm malignancy - treatment should never proceed without histological confirmation.

  • Missed surveillance in NF1

    Falling out of whole-body MRI surveillance in NF1 removes the best chance of catching transformation early.

Living with it

Vigilance, not anxiety.

Four things that make the biggest difference for people with NF1 or a history of MPNST - knowing your baseline, reporting change early, keeping surveillance appointments, and using the support that's available.

A quiet reminder

Early reporting changes outcomes more than anything else.

Most neurofibromas never turn malignant - but the few that do are far more treatable when caught early.

  1. 01 Watch

    Know your own baseline

    If you have NF1, learn the size, shape and feel of your neurofibromas so you notice a genuine change quickly.

  2. 02 Report

    Never ignore new pain

    Pain that appears or changes in a known lesion is worth reporting promptly, even if it feels minor at first.

  3. 03 Attend

    Keep surveillance appointments

    Whole-body MRI surveillance only works if it happens - missed scans are missed chances for early detection.

  4. 04 Support

    Use specialist and charity support

    Sarcoma UK and Nerve Tumours UK offer practical and emotional support alongside your specialist medical team.

Frequently asked

Everything we get asked about MPNST.

Quick answers on NF1 risk, warning signs, diagnosis and treatment.

  • What is a malignant peripheral nerve sheath tumour?

    MPNST is a rare, aggressive sarcoma that develops from Schwann cells or other cells that make up the protective sheath around peripheral nerves. It can grow quickly, invade nearby tissue and spread to other parts of the body if not treated promptly.

  • Why is neurofibromatosis type 1 relevant?

    Up to 50% of MPNSTs arise in people with NF1, usually through malignant transformation of an existing plexiform neurofibroma. Someone with NF1 carries a lifetime risk of around 10% of developing an MPNST, which is why regular surveillance matters.

  • What symptoms suggest malignant transformation?

    New or worsening pain in a known neurofibroma is the classic red flag. Other features include rapid growth, a firmer or more fixed texture, and new weakness or numbness in the distribution of the affected nerve.

  • How is MPNST diagnosed?

    MRI is the gold standard imaging test, often followed by PET-CT to help distinguish benign from malignant tissue. A core needle biopsy is mandatory to confirm the diagnosis before any treatment is planned, alongside molecular profiling and staging CT scans.

  • What is the main treatment for MPNST?

    Wide surgical resection with clear margins is the mainstay of treatment, sometimes requiring sacrifice of the affected nerve. Radiotherapy is often added for high-grade tumours or close margins, while chemotherapy is used mainly for metastatic or unresectable disease.

  • Can MPNST be prevented in people with NF1?

    There is no way to prevent MPNST outright, but whole-body MRI surveillance aims to catch malignant transformation early, when treatment is most likely to succeed. Selumetinib is approved for NF1-associated plexiform neurofibroma and may have a future role in reducing progression risk.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.